Literature DB >> 8259643

Mechanism of lymphocytic choriomeningitis virus entry into cells.

P Borrow1, M B Oldstone.   

Abstract

The path that the arenavirus lymphocytic choriomeningitis virus (LCMV) uses to enter rodent fibroblastic cell lines was dissected by infectivity and inhibition studies and immunoelectron microscopy. Lysosomotropic weak bases (chloroquine and ammonium chloride) and carboxylic ionophores (monensin and nigericin) inhibited virus entry, assessed as virus nucleoprotein expression at early times post-infection, indicating that the entry process involved a pH-dependent fusion step in intracellular vesicles. That entry occurred in vesicles rather than by direct fusion of virions with the plasma membrane was confirmed by immunoelectron microscopy. The vesicles involved were large (150-300 nm diameter), smooth-walled, and not associated with clathrin. Unlike classical phagocytosis, virus uptake in these vesicles was a microfilament-independent process, as it was not blocked by cytochalasins. LCMV entry into rodent fibroblast cell lines thus involves viropexis in large smooth-walled vesicles, followed by a pH-dependent fusion event inside the cell.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8259643     DOI: 10.1006/viro.1994.1001

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  67 in total

1.  NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs.

Authors:  K J Lee; I S Novella; M N Teng; M B Oldstone; J C de La Torre
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Identification of a novel consensus sequence at the cleavage site of the Lassa virus glycoprotein.

Authors:  O Lenz; J ter Meulen; H Feldmann; H D Klenk; W Garten
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  RING finger Z protein of lymphocytic choriomeningitis virus (LCMV) inhibits transcription and RNA replication of an LCMV S-segment minigenome.

Authors:  T I Cornu; J C de la Torre
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

4.  The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P.

Authors:  O Lenz; J ter Meulen; H D Klenk; N G Seidah; W Garten
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

5.  Identification of the lymphocytic choriomeningitis virus (LCMV) proteins required to rescue LCMV RNA analogs into LCMV-like particles.

Authors:  Ki Jeong Lee; Mar Perez; Daniel D Pinschewer; Juan Carlos de la Torre
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

6.  Endoproteolytic processing of the lymphocytic choriomeningitis virus glycoprotein by the subtilase SKI-1/S1P.

Authors:  Winfried R Beyer; Dennis Pöpplau; Wolfgang Garten; Dorothee von Laer; Oliver Lenz
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

7.  Characterization of the arenavirus RING finger Z protein regions required for Z-mediated inhibition of viral RNA synthesis.

Authors:  Tatjana I Cornu; Juan Carlos de la Torre
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

8.  Characterization of the genomic promoter of the prototypic arenavirus lymphocytic choriomeningitis virus.

Authors:  Mar Perez; Juan Carlos de la Torre
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

9.  Substitutions in the glycoprotein (GP) of the Candid#1 vaccine strain of Junin virus increase dependence on human transferrin receptor 1 for entry and destabilize the metastable conformation of GP.

Authors:  Magali E Droniou-Bonzom; Therese Reignier; Jill E Oldenburg; Alex U Cox; Colin M Exline; Jessica Y Rathbun; Paula M Cannon
Journal:  J Virol       Date:  2011-10-05       Impact factor: 5.103

10.  An antibody directed against the fusion peptide of Junin virus envelope glycoprotein GPC inhibits pH-induced membrane fusion.

Authors:  Joanne York; Jody D Berry; Ute Ströher; Qunnu Li; Heinz Feldmann; Min Lu; Meg Trahey; Jack H Nunberg
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.